Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients
This study is ongoing, but not recruiting participants.

First Received on December 28, 2007.   Last Updated on December 27, 2011   History of Changes
Sponsor: Brigham and Women's Hospital
Information provided by (Responsible Party): Daniel Jay Pallin, MD, MPH, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00676130
  Purpose

The primary aim of this study is to quantify the effectiveness of Bactrim as additional therapy for the treatment of uncomplicated cellulitis in adults, by comparing: standard therapy plus Bactrim, versus standard therapy plus placebo.

The primary hypothesis of this study is that, in light of increasing CA-MRSA prevalence, subjects treated with standard therapy plus Bactrim will have higher cure rates than those treated with standard therapy plus placebo.


Condition Intervention
Cellulitis
Drug: Cephalexin + Trimethoprim Sulfamethoxazole
Drug: Cephalexin + Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Placebo Added to Standard Treatment of Uncomplicated Cellulitis in Emergency Department Patients

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • The main outcome measure will be the relative efficacy of treatment in the two treatment arms: (a) standard therapy plus Bactrim, (b) standard therapy plus placebo. [ Time Frame: 14 days; 30 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 144
Study Start Date: May 2007
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: I Drug: Cephalexin + Placebo

Weight-based dosing in capsule or suspension form according to the following scale:

15-19 kg (33-42 lbs): Cephalexin 300 mg qid

20-24 kg (42-53 lbs): Cephalexin 400 mg qid

25-29 kg (53-64 lbs): Cephalexin 500 mg qid

29-60 kg (64-132 lbs): Cephalexin 500 mg qid

60-80 kg (132-176 lbs): Cephalexin 1000 mg tid

> 80 kg (176 lbs): Cephalexin 1000 mg qid

Experimental: II Drug: Cephalexin + Trimethoprim Sulfamethoxazole

Weight-based dosing in capsule or suspension form according to the following scale:

15-19 kg (33-42 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 40/200 mg qid; Cephalexin 300 mg qid

20-24 kg (42-53 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 60/300 mg qid; Cephalexin 400 mg qid

25-29 kg (53-64 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 72/360 mg qid; Cephalexin 500 mg qid

29-60 kg (64-132 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 80/400 mg qid; Cephalexin 500 mg qid

60 kg (132 lbs): Trimethoprim Sulfamethoxazole (Bactrim) 80/400 mg qid; Cephalexin 500 mg qid

60-80 kg (132-176 lbs): Trimethoprim Sulfamethoxazole (Bactrim) 160/800 mg tid; Cephalexin 1000 mg tid

> 80 kg (176 lbs): Trimethoprim Sulfamethoxazole (Bactrim) 160/800 mg qid; Cephalexin 1000 mg qid


  Eligibility

Ages Eligible for Study:   12 Months and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Must have cellulitis as defined here:

    1. Definition A (preferred definition):

      Recent onset of soft tissue erythema, considered by the treating clinician to be bacterial in origin, and associated with signs of infection that include at least two of the following: pain, swelling, warmth, fever, lymphangitis, induration, or ulceration.

    2. Definition B (ONLY for darkly-pigmented subjects who cannot use Definition A):

      Recent onset of soft tissue color change, pain, or swelling, considered by the treating clinician to be bacterial in origin, and at least one of the following: warmth, fever, induration, or ulceration

  • Clinical (non-research) attending physician agrees with treatment with cephalexin until 3 days after all symptoms gone, using our weight-based dosing
  • Responsible clinical attending physician comfortable with adding trimethoprim-sulfamethoxazole vs. placebo to the above
  • Subject understands the study and signs written informed consent.
  • Subject agrees to drink at least 1 liter of fluid per day.
  • Subject will commit to all follow-up appointments

Exclusion Criteria:

  • Age < 12 months or weight <15 kg
  • Current skin infection has already been treated
  • Allergy to sulfa drugs
  • History of severe allergic reaction to penicillin (defined as anaphylactoid reaction, angioedema, bronchospasm)
  • Current use of any antibiotic (other than topicals)
  • Diabetes mellitus
  • Cellulitis complicated by underlying peripheral vascular disease
  • Renal insufficiency, defined as patient report, clinical suspicion, or creatinine>1.3 or EGFR<60 on the last-available set of chemistry results in our computer system
  • Hospital admission required
  • Presence of > 1 cc of purulent discharge at any time
  • Cellulitis involving an indwelling vascular, enteric, or urinary catheter
  • Immunocompromise of any etiology
  • Pregnancy
  • Breast feeding
  • Facial cellulitis (infection is above the clavicles)
  • Cellulitis associated with marine or freshwater injury, or animal or human bite. (Insect bites not excluded.)
  • History of glucose-6-phosphate dehydrogenase deficiency
  • Taking coumadin (warfarin), methotrexate, cisapride, phenytoin (dilantin), digoxin, or dofetilide
  • Known megaloblastic anemia due to folate deficiency.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00676130

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Principal Investigator: Daniel J. Pallin, MD, MPH Brigham and Women's Hospital
  More Information

No publications provided

Responsible Party: Daniel Jay Pallin, MD, MPH, Associate Research Director, Department of Emergency Medicine, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00676130     History of Changes
Other Study ID Numbers: 2007P000414, F8349839
Study First Received: December 28, 2007
Last Updated: December 27, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:
Cellulitis
Bactrim
Trimethoprim Sulfamethoxazole
MRSA
Methicillin-resistant Staphylococcus aureus

Additional relevant MeSH terms:
Cellulitis
Emergencies
Skin Diseases, Infectious
Infection
Suppuration
Connective Tissue Diseases
Inflammation
Pathologic Processes
Disease Attributes
Cephalexin
Sulfamethoxazole
Trimethoprim
Trimethoprim-Sulfamethoxazole Combination
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Infective Agents, Urinary
Renal Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 09, 2012